Abstract
A 39-yr-old man presented to our hospital with unexplained erythrocytosis and hypertension. His follow-up for erythrocytosis had begun 2 yr earlier in another hospital and he had been diagnosed with polycythemia rubra vera. On admission to our hospital he was hypertensive (165/95 mmHg) and, except for the presence of moon-like face and facial plethora, his physical examination was normal. His hemoglobin concentration was 19.2 g/dl, and hematocrit was 58.9% with an increased red blood cell mass of 58 ml/kg as measured by radioisotope (Cr51). Blood film, other hematological indices except for elevated leukocyte alkaline phosphatase score, arterial gas analysis, and examination of aspirated bone marrow were all normal. An abdominal ultrasonography showed no evidence of splenomegaly. A diagnosis of probable secondary erythrocytosis was made. Early-morning serum cortisol and 24-h urinary free cortisol concentration as well as serum ACTH were high. Serum cortisol was not suppressed by low-dose dexamethasone, but suppressed by high-dose dexamethasone. Pituitary magnetic resonance imaging showed no lesion. After inferior petrosal sinus sampling suggesting right-central ACTH secretion, the patient underwent transnasal-transsphenoidal pituitary adenomectomy. Both hypercortisolemia and erythrocytosis regressed completely after the adenomectomy. After the operation, the patient’s hemoglobin concentration and hematocrit decreased steadily, and 1 month post-adenomectomy his hemoglobin is 14.9 g/dl and hematocrit 44.8%. Thus, Cushing’s syndrome should be a routine part of evaluation of unexplained polycythemia.
Similar content being viewed by others
References
Prchal JT. Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders. Semin Hematol 2001, 38 (Suppl 2): 10–20.
Prchal JT. Classification and molecular biology of polycythemias (erythrocytoses) and thrombocytosis. Hematol Oncol Clin North Am 2003, 17:1151–8.
McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005, 130: 174–95.
Miller WL, Tyrrell JB. Endocrinology and metabolism. New York: McGraw-Hill, 1995, 555–711.
Bauer A, Tronche F, Wessely O, et al. The glucocorticoid receptor is required for stress erythropoiesis. Genes Dev 1999, 13: 2996–3002.
von Lindern M, Zauner W, Mellitzer G, et al. The glucocorticoid receptor cooperates with the erythropoietin receptor and c-Kitto enhance and sustain proliferation of erythroid progenitors in vitro. Blood 1999, 94: 550–9.
Gordon AS, Zanjani ED, Levere RD, Kappas A. Stimulation of mammalian erythropoiesis by 5beta-H steroid metabolites. Proc Natl Acad Sci U S A 1970, 65: 919–24.
Kutti J, Ridell B. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol (Paris) 2001, 49: 164–6.
Wasserman LR. The management of polycythaemia vera. Br J Haematol 1971, 21: 371–6.
Lindemann R, Trygstad O, Halvorsen S. Pituitary control of erythropoiesis. Scand J Haematol 1969, 6: 77–86.
Leberbauer C, Boulme F, Unfried G, Huber J, Beug H, Mullner EW. Different steroids co-regulate long-term expansion versus terminal differentiation in primary human erythroid progenitors. Blood 2005, 105: 85–94.
Golde DW, Bersch N, Cline MJ. Potentiation of erythropoiesis in vitro by dexamethasone. J Clin Invest 1976, 57: 57–62.
Udupa KB, Crabtree HM, Lipschitz DA. In vitro culture of proerythroblasts: characterization of proliferative response to erythropoietin and steroids. Br J Haematol 1986, 62: 705–14.
Roodman GD, Lee J, Gidari AS. Effects of dexamethasone on erythroid colony and burst formation from human fetal liver and adult marrow. Br J Haematol 1983, 53: 621–8.
Kelly JJ, Martin A, Whitworth JA. Role of erythropoietin in cortisol-induced hypertension. J Hum Hypertens 2000, 14: 195–8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gursoy, A., Dogruk Unal, A., Ayturk, S. et al. Polycythemia as the first manifestation of Cushing’s disease. J Endocrinol Invest 29, 742–744 (2006). https://doi.org/10.1007/BF03344186
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03344186